Form 4: Amneal Pharmaceuticals' President & Co-CEO Chirag Patel Reports Stock Transactions

Chirag Patel, President & Co-CEO of Amneal Pharmaceuticals, reports the vesting and settlement of performance-based and regular restricted stock units, along with associated tax withholding.

Summary

• Chirag Patel, President & Co-CEO of Amneal Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 3, 2025, performance-based restricted stock units vested, resulting in the acquisition of 579,710 Class A Common Stock shares.
• Shares were also withheld to satisfy tax obligations related to the vesting of these units, totaling 279,527 shares at a price of $8.76.
• On March 4, 2025, restricted stock units vested, leading to the acquisition of 92,592 Class A Common Stock shares.
• An additional 47,361 shares were withheld to cover tax obligations at a price of $8.84.
• Patel also received a grant of 890,410 performance-based restricted stock units and 239,726 restricted stock units on March 3, 2025.
• Following these transactions, Patel directly owns 857,980 shares of Class A Common Stock and indirectly owns 21,269,420 shares through family trusts.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The vesting of performance-based units suggests the company met some performance goals, but the tax withholding is a standard procedure.

Positives

• The vesting of performance-based restricted stock units indicates that the company met certain performance targets, which is a positive sign.

Future Outlook

The performance-based restricted stock units granted on March 3, 2025, are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period ending February 28, 2028.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions, which investors often monitor for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation packages often include a mix of salary, stock options, and restricted stock units to align management's interests with those of shareholders.
• The vesting schedules and performance metrics associated with these equity grants are typically benchmarked against industry peers to ensure competitiveness and effectiveness in incentivizing performance.
• Companies like Teva Pharmaceutical Industries Ltd. and Viatris Inc. also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The vesting of stock options and restricted stock units can have a minor dilutive effect on existing shareholders.

Key Dates